Dosing strategies for switching from oral risperidone to paliperidone palmitate: Effects on clinical outcomes.

Hsia, Stephanie L; Leckband, Susan G; Rao, Sanjai; Jackson, Elizabeth; Lacro, Jonathan P

Hsia, Stephanie L; Leckband, Susan G; Rao, Sanjai; Jackson, Elizabeth; Lacro, Jonathan P.

Afiliação

Hsia SL; PGY-2 Psychiatric Pharmacy Resident, Veterans Affairs San Diego Healthcare System, San Diego, California, Stephanie.Hsia@va.gov.
Leckband SG; Lead Mental Health Pharmacist, Department of Psychiatry, University of California San Diego, San Diego, California; Psychiatric Clinical Pharmacy Specialist, Veterans Affairs San Diego Healthcare System, San Diego, California.
Rao S; Assistant Clinical Professor of Psychiatry and Associate Residency Training Director, University of California San Diego, and Veterans Affairs San Diego Healthcare System, San Diego, California.
Jackson E; Psychiatric Clinical Pharmacy Specialist, Veterans Affairs San Diego Healthcare System, San Diego, California.
Lacro JP; Director of Pharmacy Education and Training, Veterans Affairs San Diego Healthcare System, San Diego, California.

Ment Health Clin ; 7(3): 95-100, 2017 May.

Article em En | MEDLINE | ID: mdl-29955505

Palavras-chave

Invega Sustenna; antipsychotics; bridge; bridging; dose; dosing; hospitalizations; injectable; long-acting injectable; outcome; paliperidone palmitate; risperidone; schizoaffective; schizophrenia

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2017 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2017 Tipo de documento: Article